A cell-based backup to speed up pandemic influenza vaccine production

Trends in Microbiology

Volumn 20, Issue 3, 2012, Pages 103-105

  Lee, Min Shi ^a   Hu, Alan Yung Chih ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Cell culture; Influenza; Pandemic; Vaccine

Indexed keywords

INFLUENZA VACCINE;

AVIAN INFLUENZA VIRUS; CELL THERAPY; CLINICAL EVALUATION; GENETIC REASSORTMENT; HUMAN; INFLUENZA A (H1N1); INFLUENZA VACCINATION; NONHUMAN; NOTE; PANDEMIC INFLUENZA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; SEASONAL INFLUENZA; VACCINE PRODUCTION; VERO CELL; VIROGENESIS; VIRUS PARTICLE;

ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; CYTOLOGICAL TECHNIQUES; DOGS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; VERO CELLS;

EID: 84862814417     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2011.12.002     Document Type: Note

References (14)

1. Partridge J., Kieny M.P. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets. Vaccine 2010, 28:4709-4712.
2. Wood J.M., Williams M.S. History of inactivated influenza vaccines. Textbook of Influenza 1998, 317-323. Blackwell. R. Webster (Ed.).
3. Cox N.J., Regenery H.L. Global influenza surveillance: tracking a moving target in a rapidly changing world. Option for the Control of Influenza III 1996, 591-598. Elsevier. L.E. Brown, A.W. Hampson, R.G. Webster (Eds.).
4. Wood J.M. Selection of influenza vaccine strains and developing pandemic vaccines. Vaccine 2002, 20(Suppl. 5):B40-B44.
5. Kilbourne E.D. Future influenza vaccines and the use of genetic recombinants. Bull. World Health Organ 1969, 41:643-645.
6. Belshe R., et al. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev. Vaccines 2004, 3:643-654.
7. Patriarca, P.A. (2007) Use of cell lines for the production of influenza virus vaccines: an appraisal of technical, manufacturing, and regulatory considerations, World Health Organization, http://www.who.int/vaccine_research/diseases/influenza/WHO_Flu_Cell_Substrate_Version3.pdf.
8. Perdue M.L., et al. The future of cell culture-based influenza vaccine production. Expert Rev. Vaccines 2011, 10:1183-1194.
9. Doroshenko A., Halperin S.A. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev. Vaccines 2009, 8:679-688.
10. Barrett P.N., et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011, 377:751-759.
11. Howard M.K., et al. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol. Chem. 2008, 389:569-577.
12. Hu A.Y., et al. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines. Vaccine 2008, 26:5736-5740.
13. Tseng Y.F., et al. Adaptation of influenza H5N1 vaccine viruses in Vero cells: implications for pandemic preparedness. PloS ONE 2011, 6:e24057.
14. Minor P.D., et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 2009, 27:2907-2913.